Stevanato Group (STVN) stock is in focus after the company reported that liraglutide combination products using its Alina 30 and Alina 50 pen injectors received marketing authorizations in multiple European countries.
The Alina approvals come as Stevanato Group’s share price shows mixed momentum, with a 30 day share price return of 8.23% and a 90 day share price return of 12.08%. However, the year to date share price return is down 3.55% and the 1 year total shareholder return is down 20.69%, signalling recent interest but weaker longer term outcomes for shareholders.
If this news has you thinking more broadly about drug delivery and injectable therapies, it can be useful to see what else is on the market and review 41 healthcare AI stocks.
For Stevanato Group, the question now is whether the recent share price rebound reflects investors reassessing the underlying drug delivery business, or a short term swing in sentiment that the valuation section can help you frame.
Most Popular Narrative: 18.6% Undervalued
The most followed narrative on Stevanato Group frames a fair value of $24.39 against a last close of $19.85, which implies meaningful upside if the underlying assumptions play out as expected.
The growing prevalence of biologics and novel drug classes (including GLP-1s, mAbs, and biosimilars) is driving robust, increasing demand for Stevanato's high-value containment and delivery solutions, evidenced by high growth rates in these product lines and strong order pipelines from major pharma clients, which supports ongoing revenue expansion.
Want to understand why this narrative still assigns a premium earnings multiple and higher margin profile to Stevanato Group? The entire valuation hangs on how quickly higher value drug delivery solutions reshape its revenue mix and long term profitability.
Result: Fair Value of $24.39 (UNDERVALUED)
However, there are still real pressure points for Stevanato Group, including rising capital and operating costs, as well as heavy reliance on a small group of large biopharma customers.
Next Steps
If the mix of risks and rewards around Stevanato Group leaves you unsure, do not wait for the crowd to settle the debate. Review the 3 key rewards.
